SILVER SPRING, Md.--(BUSINESS WIRE)--False statements about a botulinum toxin strain and concerns about integrity of data and the impact on patient safety are at the core of a Citizen Petition filed ...

Government approval for wrinkle-smoothening botulinum toxin Medytoxin is proceeding as planned in China under the name Neuronox, Korean BTX maker Medytox said Wednesday in a regulatory filing. It came ...

In a deal that could net Medytox up to $362 million, the Seoul-based company will license to Allergan exclusive global rights outside Korea to develop and commercialize unspecified neurotoxin product ...

This story is part of Forbes' coverage of Asia's Best Under A Billion 2018 list, which highlights 200 Asia-Pacific public companies with less than $1 billion in revenue and consistent top- and ...

Ranbaxy Laboratories has entered into a strategic in-licensing agreement for the Indian market, with Medy-Tox Inc (Medy-Tox), South Korea's largest biotech venture, for its cosmetic product, Neuronox.

South Korean biopharma company Medytox said Wednesday that it had submitted a biologics license application for its type A botulinum toxin drug, Medytoxin, to the Taiwan Food and Drug Administration.

Drug major Ranbaxy Laboratories has entered into a deal with South Korean biotech firm Medy-Tox for marketing its cosmetic product, Neuronox, in the Indian market. HT Image Ranbaxy said it has entered ...